Clinical trials: Immune System Disorder (Healthy Volunteer)
Inflammatory Disease, Autoimmune Disease
Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols
Background: For every CHI research study, patients must fulfill a list of criteria, based primarily on their medical condition. To determine whether a patient meets these eligibility criteria to participate in a research…
- Conditions
- Inflammatory Disease, Autoimmune Disease, Immunologic Disease, Healthy Volunteers
- Trial name
- NCT00968084
- Where
- United States
- Volunteers
- 587 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hereditary Angioedema
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
This is a 3 part phase 1, randomized, double-blind, placebo-controlled, study of the safety, tolerability, and pharmacokinetics of KVD824 following administration of single and multiple ascending oral doses; followed by a…
- Trial name
- NCT05178355
- Testing
- KVD824
- Where
- United Kingdom
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- KalVista Pharmaceuticals, Ltd.
HIV Infections
Metabolic Impact Assessment of Tenofovir Disoproxil Fumarate on Non-HIV-1 Infected Healthy Adult Male Volunteers
Metabolic changes commonly occur in HIV therapy. The purpose of this study is to assess the impact on insulin sensitivity from the administration of tenofovir disoproxil fumarate 300 mg compared with placebo in non-HIV-1 infected…
- Trial name
- NCT00648817
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus (HIV) Infection
Investigation Of Safety And Pharmacokinetics Following A Single Oral Dose Of 300 Mg Maraviroc In Healthy Male Japanese Volunteers
To confirm safety and pharmacokinetics of maraviroc following a single oral dose of 300 mg maraviroc in healthy male Japanese volunteers.
- Trial name
- NCT00821535
- Testing
- maraviroc (Selzentry, Celsentri)
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Hepatitis B
Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.
The current study will evaluate immunological memory to hepatitis B antigen in subjects who received primary neonatal vaccination of hepatitis B vaccine (Engerix™-B ), 20 years ago in the primary study and who have anti-HBs…
- Trial name
- NCT00456625
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Sjogren Syndrome, Dry Syndrome
Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)
Prospective multicenter cross-sectional study evaluating ultrasound of the main salivary glands (2 parotid and 2 submandibular) in patients with Sjögren's disease compared with patients with other connective diseases (rheumatoid…
- Conditions
- Sjogren Syndrome, Dry Syndrome, Lupus, Scleroderma
- Trial name
- COUGAR (NCT06680310)
- Where
- France
- Volunteers
- 501 people
- Sponsor
- University Hospital, Brest
Rheumatoid Arthritis (RA)
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
The objective of the study is to assess the single dose PK, safety, tolerability and immunogenicity of abatacept 125mg administered SC in Chinese healthy subjects.
- Trial name
- NCT02805010
- Testing
- Abatacept
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Infection, Human Immunodeficiency Virus
Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects
The abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) 600 milligrams (mg)/50 mg/300 mg fixed-dose combination (FDC) tablet is currently approved in the United States (US) and Europe.
- Trial name
- NCT02539576
- Testing
- ABC/DTG/3TC FDC tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Osteoarthritis, Rheumatoid Arthritis
A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of DW1809
Randomized, Open-label, Oral, Single-dose, two-Sequence, four-Period, crossover study
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Back Pain, Acute Upper Respiratory Tract Infection
- Trial name
- NCT05214677
- Testing
- DW1809, DW1809-1
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102
The principal aim of this study is to obtain safety, tolerability and pharmacokinetic data when LEO 29102 is administered cutaneously as single and multiple doses to healthy subjects.
- Trial name
- NCT01423656
- Testing
- LEO 29102
- Where
- United Kingdom
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Hepatitis B
Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.
This study will evaluate the immune response of healthy subjects who received neonatal vaccination course with GSK Biologicals' Engerix™-B vaccine, approximately 20 years ago.
- Trial name
- NCT00774995
- Testing
- EngerixTM-B
- Where
- Thailand
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) in Participants With Mild or Moderate Asthma (MK-0476-380 AM3)(COMPLETED)
A study to evaluate the safety, tolerability and pharmacokinetics of inhaled Montelukast (MK-0476) in participants with mild or moderate asthma.
- Trial name
- NCT00636207
- Testing
- Montelukast
- Volunteers
- 46 people
- Sponsor
- Organon and Co
Allergic Conjunctivitis
A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults
The main goal of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profiles* of MDI-1228_mesylate Ophthalmic Solution in healthy adult participants.
- Trial name
- NCT05969236
- Testing
- MDI-1228_mesylate Ophthalmic Solution
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Medinno Pharmaceutical Technology Co., Ltd.
Type I Diabetes
Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects
The prevalence of diabetes and diabetes-associated complications is still increasing. Several major long-term complications of diabetes such as cardiovascular disease, chronic renal failure, diabetic retinopathy and others relate…
- Trial name
- NCT01843114
- Testing
- FDOCT, Dynamic Vessel Analyzer
- Where
- Austria
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Rheumatoid Arthritis
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of AZD6912 administered subcutaneously (SC) in healthy participants.
- Trial name
- NCT06115967
- Testing
- AZD6912
- Where
- 2 sites in Canada, United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Graft-versus-host Disease
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability
To assess the relative bioavailability of SHR0302 oral solution and tablet in healthy subjects. To assess the safety and tolerability of a single dose of SHR0302 oral solution and tablet.
- Trial name
- NCT05856058
- Testing
- SHR0302
- Where
- China
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA).
- Trial name
- PROTECT (NCT05476497)
- Testing
- VLP Peanut
- Where
- 10 sites in United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Allergy Therapeutics
IgA Nephropathy
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject
The study is being conducted to Evaluate the Safety, Tolerability and Pharmacokinetics pharmacodynamics of SHR-2010 by intravenously/subcutaneously in Healthy Subject.
- Trial name
- NCT05398510
- Testing
- SHR-2010 injection
- Where
- China
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic…
- Trial name
- StopRA (NCT02603146)
- Testing
- Hydroxychloroquine
- Where
- 14 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neurologic Disorders, Healthy Volunteers
Natural History of Multiple Sclerosis and Its Mimickers
Background: Magnetic resonance imaging (MRI) has been used for decades to help diagnose and monitor neurological disorders like multiple sclerosis (MS). Researchers want to improve how MRI pictures are taken.
- Conditions
- Neurologic Disorders, Healthy Volunteers, Multiple Sclerosis
- Trial name
- NCT02504840
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.